From the National Center for Advancing Translational Sciences
From the National Institutes of Health
Thursday, September 14, 2000 -
Friday, September 15, 2000
NIH Campus, Bethesda, MD
Churg-Strauss syndrome is a rare disease that is characterized by hypereosinophilia and vasculitis. Since the approval in 1996 of the new anti-leukotriene therapy for asthma, several new cases of Churg-Strauss syndrome have been diagnosed. It is not clear whether these cases are the result of an untoward effect of anti-leukotriene therapy or a primary eosinophilic disease that had been incorrectly diagnosed and treated as asthma. Several published reports suggest that the anti-leukotriene therapy allowed a reduction in corticosteroid therapy for asthma and thus unmasked the underlying condition of Churg-Strauss syndrome. This workshop explored the nature and magnitude of the association between anti-leukotriene therapy and Churg-Strauss syndrome and identified priorities for research into the pathogenesis of eosinophilic syndromes. Many of the scientific and therapeutic questions raised by the reports of Churg-Strauss syndrome being recognized in patients receiving anti-leukotriene therapy were addressed. The NIH workshop report on the relationship of asthma therapy and Churg-Strauss syndrome was published in the Journal of Allergy and Clinical Immunology in FY 2001.
Contact: Dr. Marshall Plaut (301) 496-8973Dr. Virginia Taggart (301) 435-0202
National Heart, Lung, and Blood Institute